COSMEGEN Side Effects

6955321-5 | Hepatic Failure, Venoocclusive Disease
on Aug 11, 2010 Female patient from BELGIUM , child 12 years of age, was diagnosed with nephroblastoma and was treated with Cosmegen (View Usage). Patient experienced the following unwanted or unexpected effects: hepatic failure, venoocclusive disease. Cosmegen dosage: . During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ).

6913460-9 | Acute Hepatic Failure, Coagulopathy, Hepatic Encephalopathy
Patient was taking Cosmegen (View Usage). Patient had the following side effects: acute hepatic failure, coagulopathy, hepatic encephalopathy on Jul 23, 2010 from ITALY Additional patient health information: Male patient , child 2 years of age, . Cosmegen dosage: 0.8 Mg Milligram(s), Intravenous.

6843030-2 | Pneumonia
Adverse event was reported on Jun 29, 2010 by a Female patient taking Cosmegen (View Usage) (Dosage: 0.5 Mg Milligram(s), 1 In 2wk, Intravenous (not Otherwise Specified)) was diagnosed with choriocarcinoma and. Location: JAPAN , 53 years of age, weighting 114.6 lb, After Cosmegen was administered, patient had the following side effects: pneumonia (What is pneumonia?). During the same period patient was treated with METHOTREXATE (420 Milligram(s), 1 In 2 Wk, Intravenous (not Otherwise Specified)) (View Methotrexate Review and Methotrexate Label ), LASTET (ETOPOSIDE) (INJECTION) (140 Mg Milligram(s), 1 In 2 Wk, Intravenous Drip) (View Lastet (etoposide) (injection) Review and Lastet (etoposide) (injection) Label ), CYCLOPHOSPHAMIDE (840 Mg Milligram(s0, 1 In 2 Wk, Intravenous (not Otherwise Specified)) (View Cyclophosphamide Review and Cyclophosphamide Label ), ONCOVIN (VINCRISTINE SULFATE) (INJECTION) (1.4 Mg Milligram(s), 1 In 2 Wk, Intravenous (not Otherwise Specified)) (View Oncovin (vincristine Sulfate) (injection) Review and Oncovin (vincristine Sulfate) (injection) Label ).

6751740-0 | Disseminated Intravascular Coagulation, Platelet Count Decreased
on May 19, 2010 Male patient from JAPAN , weighting 16.98 lb, was diagnosed with fibrosarcoma and was treated with Cosmegen (View Usage). Patient experienced the following unwanted or unexpected effects: disseminated intravascular coagulation, platelet count decreased. Cosmegen dosage: 0.1 Mg Milligram(s), 1 In 1 D, Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ONCOVIN (View Oncovin Review and Oncovin Label ).


6727655-0 | Lung Neoplasm Malignant, Uterine Leiomyoma
on Apr 26, 2010 Female patient from JAPAN , 53 years of age, was diagnosed with choriocarcinoma and was treated with Cosmegen (View Usage). Patient had the following side effects: lung neoplasm malignant, uterine leiomyoma. Cosmegen dosage: Intravenous. During the same period patient was treated with METHOTREXATE (View Methotrexate Review and Methotrexate Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ONCOVIN (VINCRISTINE SULFATE) (INJECTION) (View Oncovin (vincristine Sulfate) (injection) Review and Oncovin (vincristine Sulfate) (injection) Label ).

6696301-7 | Bacterial Sepsis
Patient was taking Cosmegen (View Usage). After Cosmegen was administered, patient had the following side effects: bacterial sepsis on Apr 08, 2010 from GERMANY Additional patient health information: Male patient , 14 years of age, was diagnosed with ewing's sarcoma and. Cosmegen dosage: Iv. During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), ADRIAMYCIN PFS (View Adriamycin Pfs Review and Adriamycin Pfs Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ).

6610091-5 | Dysphagia, Dysphonia, Vocal Cord Paresis
Adverse event was reported on Feb 08, 2010 by a Female patient taking Cosmegen (View Usage) (Dosage: 0.5 Mg; Iv) was diagnosed with nephroblastoma and. Location: UNITED KINGDOM , child 5 years of age, weighting 33.07 lb, Patient experienced the following unwanted or unexpected effects: dysphagia, dysphonia, vocal cord paresis. During the same period patient was treated with VINCRISTINE (Iv) (View Vincristine Review and Vincristine Label ), DOXORUBICIN HCL (Iv) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ). Patient was hospitalized.

6609485-3 | Activities Of Daily Living Impaired, Altered State Of Consciousness, Anuria, Bacterial Infection, Bedridden, Blood Creatinine Increased, Bone Marrow Failure, Continuous Haemodiafiltration, Disseminated Intravascular Coagulation
on Feb 12, 2010 Female patient from UNITED STATES , 15 years of age, weighting 92.59 lb, was diagnosed with rhabdomyosarcoma, vomiting and was treated with Cosmegen (View Usage). Patient had the following side effects: activities of daily living impaired, altered state of consciousness, anuria, bacterial infection (What is bacterial infection?), bedridden, blood creatinine increased, bone marrow failure, continuous haemodiafiltration, disseminated intravascular coagulation. Cosmegen dosage: 0.63 Mg;qd;iv. During the same period patient was treated with ETOPOSIDE (150 Mg;qd;iv) (View Etoposide Review and Etoposide Label ), IFOMIDE (IFOSFAMIDE) (2400 Mg;qd;iv) (View Ifomide (ifosfamide) Review and Ifomide (ifosfamide) Label ), ONCOVIN (2 Mg;qw;iv) (View Oncovin Review and Oncovin Label ), DORMICUM (NITRAZEPAM) (150 Mg; Iv, 100 Mg; ;iv) (View Dormicum (nitrazepam) Review and Dormicum (nitrazepam) Label ). Patient was hospitalized and became disabled.

6589096-9 | Anuria, Bacterial Infection, Bedridden, Blood Creatinine Increased, Depressed Level Of Consciousness, Dialysis, Respiratory Failure, Rhabdomyolysis
on Jan 28, 2010 Female patient from UNITED STATES , 15 years of age, weighting 92.59 lb, was diagnosed with rhabdomyosarcoma, vomiting and was treated with Cosmegen (View Usage). After Cosmegen was administered, patient had the following side effects: anuria, bacterial infection (What is bacterial infection?), bedridden, blood creatinine increased, depressed level of consciousness, dialysis (What is dialysis?), respiratory failure, rhabdomyolysis. Cosmegen dosage: 0.63 Mg; Qd; Iv. During the same period patient was treated with ETOPOSIDE (150 Mg; Qd; Iv) (View Etoposide Review and Etoposide Label ), IFOMIDE (IFOSFAMIDE) (2400 Mg; Qd; Iv) (View Ifomide (ifosfamide) Review and Ifomide (ifosfamide) Label ), ONCOVIN (2 Mg; Qw; Iv) (View Oncovin Review and Oncovin Label ), DORMICUM (NITRAZEPAM) (150 Mg; Iv, 100 Mg; Iv) (View Dormicum (nitrazepam) Review and Dormicum (nitrazepam) Label ). Patient was hospitalized and became disabled.

6580221-2 | Blood Bilirubin Increased, Bone Marrow Failure, Gamma-glutamyltransferase Increased, Gastrointestinal Haemorrhage, Intra-abdominal Haemorrhage, Localised Intraabdominal Fluid Collection, Metabolic Acidosis, Multi-organ Disorder, Peritoneal Haemorrhage
Patient was taking Cosmegen (View Usage). Patient experienced the following unwanted or unexpected effects: blood bilirubin increased, bone marrow failure, gamma-glutamyltransferase increased, gastrointestinal haemorrhage, intra-abdominal haemorrhage, localised intraabdominal fluid collection, metabolic acidosis, multi-organ disorder, peritoneal haemorrhage on Jan 19, 2010 from CROATIA (local name: Hrvatska) Additional patient health information: Male patient , child 8 years of age, was diagnosed with rhabdomyosarcoma and. Cosmegen dosage: . During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ).

6518077-6 | Anuria, Dialysis, Rhabdomyolysis
Adverse event was reported on Dec 08, 2009 by a Female patient taking Cosmegen (View Usage) (Dosage: 0.63 Mg;qd;iv) . Location: UNITED STATES , 15 years of age, weighting 92.59 lb, Patient had the following side effects: anuria, dialysis (What is dialysis?), rhabdomyolysis. During the same period patient was treated with ETOPOSIDE (150 Mg;qd;iv) (View Etoposide Review and Etoposide Label ), IFOMIDE (IFOSFAMIDE) (2400 Mg;qd;iv) (View Ifomide (ifosfamide) Review and Ifomide (ifosfamide) Label ), ONCOVIN (2 Mg;qw;iv) (View Oncovin Review and Oncovin Label ). Patient was hospitalized.

6472589-2 | Abdominal Infection, Dialysis, Renal Failure Acute, Tumour Lysis Syndrome
on Nov 13, 2009 Female patient from UNITED STATES , 54 years of age, was diagnosed with rhabdomyosarcoma and was treated with Cosmegen (View Usage). After Cosmegen was administered, patient had the following side effects: abdominal infection, dialysis (What is dialysis?), renal failure acute, tumour lysis syndrome. Cosmegen dosage: ; Iv. During the same period patient was treated with ONCOVIN (View Oncovin Review and Oncovin Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

6438544-3 | Bone Marrow Failure, Cheilitis, Dermatitis, Hypocalcaemia, Mucosal Inflammation, Nausea, Overdose, Pyrexia, Skin Erosion
on Oct 29, 2009 Female patient from JAPAN , 28 years of age, was diagnosed with rhabdomyosarcoma and was treated with Cosmegen (View Usage). Patient experienced the following unwanted or unexpected effects: bone marrow failure, cheilitis, dermatitis, hypocalcaemia, mucosal inflammation, nausea (What is nausea?), overdose, pyrexia, skin erosion. Cosmegen dosage: 2.25 Mg;qd;iv. During the same period patient was treated with IFOSFAMIDE (Iv) (View Ifosfamide Review and Ifosfamide Label ). Patient was hospitalized.

6423816-9 | Neutropenic Sepsis, Renal Failure Acute, Toxic Epidermal Necrolysis, Tumour Lysis Syndrome
Patient was taking Cosmegen (View Usage). Patient had the following side effects: neutropenic sepsis, renal failure acute, toxic epidermal necrolysis, tumour lysis syndrome on Oct 13, 2009 from UNITED KINGDOM Additional patient health information: Female patient , 62 years of age, was diagnosed with gestational trophoblastic tumour and. Cosmegen dosage: ; Iv. During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), BECLOMETHASONE DIPROPIONATE (View Beclomethasone Dipropionate Review and Beclomethasone Dipropionate Label ), ALBUTEROL (View Albuterol Review and Albuterol Label ).

6414391-3 | Bone Marrow Failure, Mucosal Inflammation, Pyrexia, Skin Erosion
Adverse event was reported on Oct 09, 2009 by a Female patient taking Cosmegen (View Usage) (Dosage: 2.25 Mg; Qd; Iv) was diagnosed with rhabdomyosarcoma and. Location: UNITED STATES , 28 years of age, After Cosmegen was administered, patient had the following side effects: bone marrow failure, mucosal inflammation, pyrexia, skin erosion. During the same period patient was treated with IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), ONCOVIN (View Oncovin Review and Oncovin Label ). Patient was hospitalized.

6388611-8 | Gestational Trophoblastic Tumour, Malignant Neoplasm Progression, Neutropenic Sepsis, Therapeutic Agent Toxicity
on Sep 15, 2009 Female patient from UNITED KINGDOM , 48 years of age, was diagnosed with gestational trophoblastic tumour and was treated with Cosmegen (View Usage). Patient experienced the following unwanted or unexpected effects: gestational trophoblastic tumour, malignant neoplasm progression, neutropenic sepsis, therapeutic agent toxicity. Cosmegen dosage: . During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6388610-6 | Neutropenic Sepsis, Therapeutic Agent Toxicity
on Sep 15, 2009 Female patient from UNITED KINGDOM , 60 years of age, was diagnosed with choriocarcinoma and was treated with Cosmegen (View Usage). Patient had the following side effects: neutropenic sepsis, therapeutic agent toxicity. Cosmegen dosage: . During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ).

6388425-9 | Choriocarcinoma, Malignant Neoplasm Progression, Neutropenic Sepsis, Therapeutic Agent Toxicity
Patient was taking Cosmegen (View Usage). After Cosmegen was administered, patient had the following side effects: choriocarcinoma, malignant neoplasm progression, neutropenic sepsis, therapeutic agent toxicity on Sep 15, 2009 from UNITED KINGDOM Additional patient health information: Female patient , 59 years of age, was diagnosed with choriocarcinoma and. Cosmegen dosage: . During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ).

6388407-7 | Neutropenic Sepsis
Adverse event was reported on Sep 15, 2009 by a Female patient taking Cosmegen (View Usage) (Dosage: ) was diagnosed with choriocarcinoma and. Location: UNITED KINGDOM , 24 years of age, Patient experienced the following unwanted or unexpected effects: neutropenic sepsis. During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6388377-1 | Neutropenic Sepsis
on Sep 15, 2009 Female patient from UNITED KINGDOM , 40 years of age, was diagnosed with gestational trophoblastic tumour and was treated with Cosmegen (View Usage). Patient had the following side effects: neutropenic sepsis. Cosmegen dosage: . During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

6242074-1 | Bone Marrow Failure, Hepatic Neoplasm, Liver Transplant, Neoplasm Recurrence, Sepsis
on Jun 10, 2009 Male patient from UNITED STATES , 15 years of age, was diagnosed with undifferentiated sarcoma and was treated with Cosmegen (View Usage). After Cosmegen was administered, patient had the following side effects: bone marrow failure, hepatic neoplasm, liver transplant (What is liver transplant?), neoplasm recurrence, sepsis (What is sepsis?). Cosmegen dosage: 0.5 Mg;qd. During the same period patient was treated with VINCRISTINE (2 Mg;qd) (View Vincristine Review and Vincristine Label ), CYCLOPHOSPHAMIDE (2.2 Mg;qd) (View Cyclophosphamide Review and Cyclophosphamide Label ).

6234449-1 | Convulsion
Patient was taking Cosmegen (View Usage). Patient experienced the following unwanted or unexpected effects: convulsion on Jun 05, 2009 from UNITED STATES Additional patient health information: Female patient , 38 years of age, weighting 130.1 lb, was diagnosed with choriocarcinoma and. Cosmegen dosage: 0.5 Mg; Ivdrp; 0.5 Mg; Ivdrp. During the same period patient was treated with SEROTONE (View Serotone Review and Serotone Label ), DECADRON (View Decadron Review and Decadron Label ), NEOPHAGEN (View Neophagen Review and Neophagen Label ), TATHION (View Tathion Review and Tathion Label ). Patient was hospitalized.

6215737-1 | Blood Lactic Acid Increased, Constipation, Hypoglycaemia, Multi-organ Failure, Tonsillitis, Venoocclusive Liver Disease
Adverse event was reported on May 22, 2009 by a Male patient taking Cosmegen (View Usage) (Dosage: ;qw; Iv) was diagnosed with renal neoplasm and. Location: UNITED STATES , weighting 35.27 lb, Patient had the following side effects: blood lactic acid increased, constipation (What is constipation?), hypoglycaemia, multi-organ failure, tonsillitis, venoocclusive liver disease. During the same period patient was treated with VINCRISTINE (1.5 Mg/m**2; Qw; Iv, ; Qw;) (View Vincristine Review and Vincristine Label ), HAMILTON ULTRABLOCK SPF 70 (View Hamilton Ultrablock Spf 70 Review and Hamilton Ultrablock Spf 70 Label ), EZILZX SYRUP (LACTULOSE) (View Ezilzx Syrup (lactulose) Review and Ezilzx Syrup (lactulose) Label ), ALKALINE MOUTH WASH (View Alkaline Mouth Wash Review and Alkaline Mouth Wash Label ). Patient was hospitalized.

6208275-3 | Activated Partial Thromboplastin Time Prolonged, Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Bilirubin Increased, Blood Bilirubin Unconjugated Increased, Blood Lactic Acid Increased, Constipation, Fibrin D Dimer Increased, Haemoglobin Decreased
on May 13, 2009 Male patient from UNITED STATES , weighting 35.27 lb, was diagnosed with renal neoplasm and was treated with Cosmegen (View Usage). After Cosmegen was administered, patient had the following side effects: activated partial thromboplastin time prolonged, alanine aminotransferase increased, aspartate aminotransferase increased, blood bilirubin increased, blood bilirubin unconjugated increased, blood lactic acid increased, constipation (What is constipation?), fibrin d dimer increased, haemoglobin decreased. Cosmegen dosage: Qw; Iv Qw; Iv. During the same period patient was treated with VINCRISTINE (1.5 Mg/m**2;qw;iv; Qw;qw;qw) (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

6196867-X | Leukopenia, Malignant Neoplasm Progression, Nephroblastoma
on May 04, 2009 Female patient from TURKEY , 16 years of age, was diagnosed with nephroblastoma and was treated with Cosmegen (View Usage). Patient experienced the following unwanted or unexpected effects: leukopenia, malignant neoplasm progression, nephroblastoma. Cosmegen dosage: . During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

6189400-X | Activated Partial Thromboplastin Time Prolonged, Ascites, Blood Lactic Acid Increased, Fibrin D Dimer Increased, Haemoglobin Decreased, Hepatomegaly, Hypoglycaemia, Lethargy, Multi-organ Failure
Patient was taking Cosmegen (View Usage). Patient had the following side effects: activated partial thromboplastin time prolonged, ascites, blood lactic acid increased, fibrin d dimer increased, haemoglobin decreased, hepatomegaly, hypoglycaemia, lethargy, multi-organ failure on May 01, 2009 from UNITED STATES Additional patient health information: Male patient , weighting 35.27 lb, was diagnosed with renal neoplasm and. Cosmegen dosage: ; Qw; Iv. During the same period patient was treated with VINCRISTINE (1.5 Mg/m882; Qw; Iv) (View Vincristine Review and Vincristine Label ). Patient was hospitalized.

6081485-4 | Bone Marrow Failure, Microangiopathy, Poor Sucking Reflex, Pyrexia, Renal Impairment, Urine Output Decreased, Vomiting
Adverse event was reported on Jan 30, 2009 by a Male patient taking Cosmegen (View Usage) (Dosage: 0.045mg; Iv; 0.07 Mg; Iv; 0.045 Mg; Iv) was diagnosed with fibrosarcoma and. Location: JAPAN , weighting 13.23 lb, After Cosmegen was administered, patient had the following side effects: bone marrow failure, microangiopathy, poor sucking reflex, pyrexia, renal impairment, urine output decreased, vomiting. During the same period patient was treated with ONCOVIN (0.24 Mg;iv; 0.37 Mg;iv) (View Oncovin Review and Oncovin Label ), DOXORUBICIN HCL (Iv) (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), IFOSFAMIDE (Iv) (View Ifosfamide Review and Ifosfamide Label ). Patient was hospitalized.

6012725-5 | Inappropriate Antidiuretic Hormone Secretion
on Nov 26, 2008 Female patient from JAPAN , child 12 years of age, was diagnosed with renal cancer and was treated with Cosmegen (View Usage). Patient experienced the following unwanted or unexpected effects: inappropriate antidiuretic hormone secretion. Cosmegen dosage: . During the same period patient was treated with VINCRISTINE (View Vincristine Review and Vincristine Label ).

6009092-X | Brain Oedema, Respiratory Failure, Thrombocytopenia
on Dec 03, 2008 Female patient from GERMANY , 27 years of age, was diagnosed with gestational trophoblastic tumour and was treated with Cosmegen (View Usage). Patient had the following side effects: brain oedema, respiratory failure, thrombocytopenia. Cosmegen dosage: 0.5 Mg; Iv. During the same period patient was treated with ETOPOSIDE (100 Mg/m**2; Iv) (View Etoposide Review and Etoposide Label ), SODIUM PERCHLORATE (View Sodium Perchlorate Review and Sodium Perchlorate Label ), METHIMAZOLE (View Methimazole Review and Methimazole Label ), PROPRANOLOL (View Propranolol Review and Propranolol Label ), METHOTREXATE (100 Mg/m**2; 200 Mg/m**2; Iv) (View Methotrexate Review and Methotrexate Label ), LEUCOVORIN CALCIUM (15 Mg; Iv) (View Leucovorin Calcium Review and Leucovorin Calcium Label ).

5615740-6 | Blood Potassium Decreased, Febrile Neutropenia, Haemoglobin Decreased, Neutropenic Sepsis, Platelet Count Decreased
Patient was taking Cosmegen (View Usage). After Cosmegen was administered, patient had the following side effects: blood potassium decreased, febrile neutropenia, haemoglobin decreased, neutropenic sepsis, platelet count decreased on Jan 22, 2008 from UNITED STATES Additional patient health information: Male patient , 32 years of age, was diagnosed with germ cell cancer and. Cosmegen dosage: 1.6 Mg/m**2; Q2w; Iv. During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), ACETAZOLAMIDE (View Acetazolamide Review and Acetazolamide Label ), DEXTROSE WITH POTASSIUM BICARBONATE AND S (View Dextrose With Potassium Bicarbonate And S Review and Dextrose With Potassium Bicarbonate And S Label ), .. (View .. Review and .. Label ), FILGRASTIM (View Filgrastim Review and Filgrastim Label ), FOLINIC ACID (View Folinic Acid Review and Folinic Acid Label ).

5615734-0 | Blood Albumin Decreased, Blood Bicarbonate Decreased, Blood Bilirubin Increased, Blood Calcium Decreased, Blood Chloride Increased, Blood Creatine Increased, Blood Phosphorus Decreased, Blood Potassium Decreased, Febrile Neutropenia
Adverse event was reported on Jan 22, 2008 by a Male patient taking Cosmegen (View Usage) (Dosage: 2 Mg; Q2w; Iv) was diagnosed with germ cell cancer and. Location: UNITED STATES , 40 years of age, Patient experienced the following unwanted or unexpected effects: blood albumin decreased, blood bicarbonate decreased, blood bilirubin increased, blood calcium decreased, blood chloride increased, blood creatine increased, blood phosphorus decreased, blood potassium decreased, febrile neutropenia. During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), DEXTROSE WITH POTASSIUM BICARBONATE AND S (View Dextrose With Potassium Bicarbonate And S Review and Dextrose With Potassium Bicarbonate And S Label ), .. (View .. Review and .. Label ), FILGRASTIM (View Filgrastim Review and Filgrastim Label ), FOLINIC ACID (View Folinic Acid Review and Folinic Acid Label ).

5615732-7 | Choriocarcinoma, Febrile Neutropenia, Haemoglobin Decreased, Intra-abdominal Haemorrhage, Platelet Count Decreased, Tumour Necrosis, White Blood Cell Count Decreased
on Jan 22, 2008 Male patient from UNITED STATES , 42 years of age, was diagnosed with germ cell cancer and was treated with Cosmegen (View Usage). Patient had the following side effects: choriocarcinoma, febrile neutropenia, haemoglobin decreased, intra-abdominal haemorrhage, platelet count decreased, tumour necrosis, white blood cell count decreased. Cosmegen dosage: 1.6 Mg; Q2w; Iv. During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), ACETAZOLAMIDE (View Acetazolamide Review and Acetazolamide Label ), DEXTROSE WITH POTASSIUM (View Dextrose With Potassium Review and Dextrose With Potassium Label ), .. (View .. Review and .. Label ), FILGRASTIM (View Filgrastim Review and Filgrastim Label ), FOLINIC ACID (View Folinic Acid Review and Folinic Acid Label ).

5494850-0 | Bone Marrow Failure, Diarrhoea, Skin Exfoliation, Stomatitis
on Oct 08, 2007 Female patient from JAPAN , 30 years of age, was diagnosed with benign hydatidiform mole, neutropenia and was treated with Cosmegen (View Usage). After Cosmegen was administered, patient had the following side effects: bone marrow failure, diarrhoea, skin exfoliation, stomatitis. Cosmegen dosage: ;qd;iv. During the same period patient was treated with METHOTREXATE (;qd) (View Methotrexate Review and Methotrexate Label ), ETOPOSIDE (;qd;) (View Etoposide Review and Etoposide Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ).

5074176-X | Adrenal Neoplasm, Choriocarcinoma, Disseminated Intravascular Coagulation, Flank Pain, Haematoma, Pneumonia, Pulmonary Haemorrhage, Respiratory Failure, Shock Haemorrhagic
Patient was taking Cosmegen (View Usage). Patient experienced the following unwanted or unexpected effects: adrenal neoplasm, choriocarcinoma, disseminated intravascular coagulation, flank pain, haematoma, pneumonia (What is pneumonia?), pulmonary haemorrhage, respiratory failure, shock haemorrhagic on Jul 26, 2006 from JAPAN Additional patient health information: Female patient , 20 years of age, was diagnosed with choriocarcinoma and. Cosmegen dosage: . During the same period patient was treated with METHOTREXATE (View Methotrexate Review and Methotrexate Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ).

5069800-1 | Disseminated Intravascular Coagulation, Pneumonia, Pulmonary Haemorrhage, Respiratory Failure
Adverse event was reported on Jul 17, 2006 by a Female patient taking Cosmegen (View Usage) (Dosage: ) was diagnosed with choriocarcinoma and. Location: JAPAN , 20 years of age, Patient had the following side effects: disseminated intravascular coagulation, pneumonia (What is pneumonia?), pulmonary haemorrhage, respiratory failure. During the same period patient was treated with METHOTREXATE (View Methotrexate Review and Methotrexate Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ).

4984568-2 | Neutropenia, White Blood Cell Count Decreased
on Apr 18, 2006 Male patient from UNITED STATES , 34 years of age, weighting 154.3 lb, was diagnosed with neoplasm malignant and was treated with Cosmegen (View Usage). After Cosmegen was administered, patient had the following side effects: neutropenia, white blood cell count decreased. Cosmegen dosage: 0.5 Mg; Qd; Iv. During the same period patient was treated with VINCRISTINE SULFATE (1.8 Mg, Qd; Iv) (View Vincristine Sulfate Review and Vincristine Sulfate Label ), IFOSFAMIDE (3.7 Gm, Qd; Iv) (View Ifosfamide Review and Ifosfamide Label ), DOXORUBICIN HYDROCHLORIDE (37 Mg, Qd; Iv) (View Doxorubicin Hydrochloride Review and Doxorubicin Hydrochloride Label ). Patient was hospitalized.

4941873-3 | Aphagia, Aphasia, Aphthous Stomatitis, Glossitis, Oral Mucosa Erosion, Swollen Tongue
on Feb 22, 2006 Male patient from JAPAN , 14 years of age, was diagnosed with rhabdomyosarcoma and was treated with Cosmegen (View Usage). Patient experienced the following unwanted or unexpected effects: aphagia, aphasia (What is aphasia?), aphthous stomatitis, glossitis, oral mucosa erosion, swollen tongue. Cosmegen dosage: 0.73 Mg; Qd; Iv. During the same period patient was treated with ETOPOSIDE (150 Mg;) (View Etoposide Review and Etoposide Label ), IFOSFAMIDE (2700 Mg; Iv) (View Ifosfamide Review and Ifosfamide Label ), VINCRISTINE (2 Mg;) (View Vincristine Review and Vincristine Label ), CISPLATIN (View Cisplatin Review and Cisplatin Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), PIRARUBICIN (View Pirarubicin Review and Pirarubicin Label ). Patient was hospitalized.

4783894-X | Febrile Neutropenia
Patient was taking Cosmegen (View Usage). Patient had the following side effects: febrile neutropenia on Sep 07, 2005 from AUSTRIA Additional patient health information: Male patient , 13 years of age, was diagnosed with ewing's sarcoma and. Cosmegen dosage: . During the same period patient was treated with VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ). Patient was hospitalized.

4783893-8 | Febrile Neutropenia
Adverse event was reported on Sep 07, 2005 by a Male patient taking Cosmegen (View Usage) (Dosage: ) was diagnosed with ewing's sarcoma and. Location: AUSTRIA , child 10 years of age, After Cosmegen was administered, patient had the following side effects: febrile neutropenia. During the same period patient was treated with VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ). Patient was hospitalized.

4783891-4 | Febrile Neutropenia
on Sep 07, 2005 Male patient from AUSTRIA , 14 years of age, was diagnosed with ewing's sarcoma and was treated with Cosmegen (View Usage). Patient experienced the following unwanted or unexpected effects: febrile neutropenia. Cosmegen dosage: . During the same period patient was treated with VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

4783889-6 | Febrile Neutropenia
on Sep 07, 2005 Male patient from AUSTRIA , 15 years of age, was diagnosed with ewing's sarcoma and was treated with Cosmegen (View Usage). Patient had the following side effects: febrile neutropenia. Cosmegen dosage: . During the same period patient was treated with VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

4783887-2 | Febrile Neutropenia
Patient was taking Cosmegen (View Usage). After Cosmegen was administered, patient had the following side effects: febrile neutropenia on Sep 07, 2005 from AUSTRIA Additional patient health information: Male patient , 15 years of age, was diagnosed with ewing's sarcoma and. Cosmegen dosage: . During the same period patient was treated with VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

4749735-1 | Haemolytic Anaemia
Adverse event was reported on Sep 03, 1998 by a Female patient taking Cosmegen (View Usage) (Dosage: ) was diagnosed with rhabdomyosarcoma and. Location: JAPAN , child 2 years of age, weighting 30.86 lb, Patient experienced the following unwanted or unexpected effects: haemolytic anaemia. During the same period patient was treated with ONCOVIN (View Oncovin Review and Oncovin Label ), ENDOXAN (View Endoxan Review and Endoxan Label ). Patient was hospitalized.

4744985-2 | Cardiac Arrest, Leukaemia, Myelodysplastic Syndrome
on Aug 05, 2005 Female patient from UNITED STATES , child 11 years of age, was diagnosed with nephroblastoma and was treated with Cosmegen (View Usage). Patient had the following side effects: cardiac arrest (What is cardiac arrest?), leukaemia, myelodysplastic syndrome. Cosmegen dosage: . During the same period patient was treated with VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), DOXORUBICIN (View Doxorubicin Review and Doxorubicin Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ).

4719146-3 | Convulsion, Inappropriate Antidiuretic Hormone Secretion
on Jun 15, 2005 Male patient from JAPAN , child 5 years of age, was diagnosed with aesthesioneuroblastoma and was treated with Cosmegen (View Usage). After Cosmegen was administered, patient had the following side effects: convulsion, inappropriate antidiuretic hormone secretion. Cosmegen dosage: . During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ), ONCOVIN (View Oncovin Review and Oncovin Label ).

4719145-1 | Renal Artery Stenosis, Renal Atrophy
Patient was taking Cosmegen (View Usage). Patient experienced the following unwanted or unexpected effects: renal artery stenosis, renal atrophy on Apr 26, 2005 from JAPAN Additional patient health information: Male patient , 42 years of age, was diagnosed with testicular germ cell tumour mixed stage iii and. Cosmegen dosage: . During the same period patient was treated with CISPLATIN (View Cisplatin Review and Cisplatin Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), BLEOMYCIN (View Bleomycin Review and Bleomycin Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), VINBLASTINE SULFATE (View Vinblastine Sulfate Review and Vinblastine Sulfate Label ). Patient was hospitalized.

4711387-4 | Anorexia, Growth Retardation, Hypothyroidism, Vomiting
Adverse event was reported on Jul 01, 2005 by a Female patient taking Cosmegen (View Usage) (Dosage: ) was diagnosed with malignant mesenchymoma and. Location: GERMANY , child 10 years of age, weighting 61.73 lb, Patient had the following side effects: anorexia, growth retardation, hypothyroidism, vomiting. During the same period patient was treated with IFOSFAMIDE (View Ifosfamide Review and Ifosfamide Label ), VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ), ETOPOSIDE (View Etoposide Review and Etoposide Label ), CARBOPLATIN (View Carboplatin Review and Carboplatin Label ), EPIRUBICIN HYDROCHLORIDE (View Epirubicin Hydrochloride Review and Epirubicin Hydrochloride Label ).

4710743-8 | Convulsion, Inappropriate Antidiuretic Hormone Secretion
on Jun 15, 2005 Male patient from JAPAN , child 5 years of age, was diagnosed with aesthesioneuroblastoma and was treated with Cosmegen (View Usage). After Cosmegen was administered, patient had the following side effects: convulsion, inappropriate antidiuretic hormone secretion. Cosmegen dosage: . During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ), ONCOVIN (View Oncovin Review and Oncovin Label ).

4699449-1 | Convulsion, Inappropriate Antidiuretic Hormone Secretion, Rhabdomyosarcoma
on Jun 15, 2005 Male patient from , child 5 years of age, was diagnosed with aesthesioneuroblastoma and was treated with Cosmegen (View Usage). Patient experienced the following unwanted or unexpected effects: convulsion, inappropriate antidiuretic hormone secretion, rhabdomyosarcoma. Cosmegen dosage: . During the same period patient was treated with ENDOXAN (View Endoxan Review and Endoxan Label ), ONCOVIN (View Oncovin Review and Oncovin Label ).

4698289-7 | Malignant Neoplasm Progression, Neoplasm Recurrence, Nephroblastoma
Patient was taking Cosmegen (View Usage). Patient had the following side effects: malignant neoplasm progression, neoplasm recurrence, nephroblastoma on May 31, 2005 from Additional patient health information: Female patient , child 6 years of age, was diagnosed with nephroblastoma and. Cosmegen dosage: . During the same period patient was treated with VINCRISTINE SULFATE (View Vincristine Sulfate Review and Vincristine Sulfate Label ).